Chen, Robert W.
Palmer, Joycelynne M.
Tomassetti, Sarah
Popplewell, Leslie L.
Alluin, Jessica
Chomchan, Pritsana
Nademanee, Auayporn P.
Siddiqi, Tanya
Tsai, Ni-Chun
Chen, Lu
Zuo, Fay
Abary, Rosemarie
Cai, Ji-lian
Herrera, Alex F.
Rossi, John J.
Rosen, Steven T.
Forman, Stephen J.
Kwak, Larry W.
Holmberg, Leona A.
Funding for this research was provided by:
Millennium Pharmaceuticals
National Cancer Institute (5 K12 CA001727, P50 CA107399, 3 P30 CA033572-S4)
Article History
Received: 4 May 2018
Accepted: 19 June 2018
First Online: 28 June 2018
Ethics approval and consent to participate
: This study was conducted according to the ethical principles for medical research involving human subjects as stated in the Declaration of Helsinki and in the ICH Good Clinical Practice guidelines. The study protocol was reviewed and approved by the Institutional Review Boards of the City of Hope National Medical Center (reference number 10137) and the Fred Hutchinson Cancer Research Center (reference number 2620). All eligible participants had the study, timelines, and outcome measures of the study explained to them. Participants were informed that they are free to discontinue participation at any time without consequence. To indicate consent, all participants signed the written informed consent form.
: Not applicable
: RC has received research funding from Takeda/Millennium Pharmaceuticals. RC has been a consultant for Takeda/Millennium. LAH has received research funding from Takeda/Millennium Pharmaceuticals, Seattle Genetics, Merck, and Sanofi. LAH has been a consultant for Seattle Genetics, Jazz, and NCCN. LAH has received royalty from Up-To-Date.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.